Clinicopathologic Characters of Renal Cell Carcinoma in Young PatientsNCT06730997
Clinicopathological Features of Renal Cell Carcinoma in Young Patients
An observational study of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients, run by Assiut University.
Trial summary
Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2025to 1 Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with renal cell carcinoma 40 years or younger at Radiation Oncology Department, South Egypt Cancer Institute, clinical oncology Assuit University at the period from 2015 to 2022
Who may be able to join
- Age < 40 years
- Patients proven to have RCC
- Patients eligible to receive treatment
Who cannot join
- Second malignancy.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Clinicopathological Features of Renal Cell Carcinoma in Young Patients and it's Influence on the Survival Outcome
Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes
Read the detailed description
Worldwide, RCC accounts for 2-3% of All adult malignancies and the 8th most commonly diagnosed primary cancer among all adults.
Representing 3rd place among urinary system tumors. Most of RCC occurs in old age while about 7% occurs in younger adults below 40 years.
Recently the published data about the tumor Clinco-pathological features, treatment response and outcomes were different in young adults than older patients, where some data showed favorable features and survivals, while other showed negative ones.
What is being measured
The primary outcome is the main question the study is designed to answer.
Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes
Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes
Measured: Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patient in period from 2010 -2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2024
- Study start1 Jan 2025 (estimated)
- Primary completion1 Feb 2027 (estimated)
- Study completion1 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Clinicopathologic Characters of Renal Cell Carcinoma in Young PatientsStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dina Gamal Abdelaziz Farrag, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06730997
- Sponsor's protocol ID
- Renal cell carcinoma
- Status last verified
- Dec 2024
- First submitted
- 9 Dec 2024
- Last updated
- 12 Dec 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006 Dec;176(6 Pt 1):2353-8. doi: 10.1016/j.juro.2006.07.130.
PubMed 17085101Suh JH, Oak T, Ro JY, Truong LD, Ayala AG, Shen SS. Clinicopathologic features of renal cell carcinoma in young adults: a comparison study with renal cell carcinoma in older patients. Int J Clin Exp Pathol. 2009;2(5):489-93. Epub 2009 Jan 30.
PubMed 19294008Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016 Jul;70(1):93-105. doi: 10.1016/j.eururo.2016.02.029. Epub 2016 Feb 28.
PubMed 26935559
Study at a glance
From the registry record, last updated by the sponsor on 12 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinicopathological Features of Renal Cell Carcinoma in Young Patients and it's Influence on the Survival Outcome
- ClinicalTrials.gov ID
- NCT06730997
- Acronym / sponsor ID
- Renal cell carcinoma
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jan 2025 (estimated)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 1 Apr 2027 (estimated)
- First posted
- 12 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes
Detailed description
Worldwide, RCC accounts for 2-3% of All adult malignancies and the 8th most commonly diagnosed primary cancer among all adults.
Representing 3rd place among urinary system tumors. Most of RCC occurs in old age while about 7% occurs in younger adults below 40 years.
Recently the published data about the tumor Clinco-pathological features, treatment response and outcomes were different in young adults than older patients, where some data showed favorable features and survivals, while other showed negative ones.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with renal cell carcinoma 40 years or younger at Radiation Oncology Department, South Egypt Cancer Institute, clinical oncology Assuit University at the period from 2015 to 2022
Key inclusion criteria (3 listed)
- Age < 40 years
Key exclusion criteria (1 listed)
- Second malignancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes
Time frame: Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patient in period from 2010 -2024
Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Dec 2024.
- Background: PubMed 17085101Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006 Dec;176(6 Pt 1):2353-8. doi: 10.1016/j.juro.2006.07.130.
- Background: PubMed 19294008Suh JH, Oak T, Ro JY, Truong LD, Ayala AG, Shen SS. Clinicopathologic features of renal cell carcinoma in young adults: a comparison study with renal cell carcinoma in older patients. Int J Clin Exp Pathol. 2009;2(5):489-93. Epub 2009 Jan 30.
- Background: PubMed 26935559Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016 Jul;70(1):93-105. doi: 10.1016/j.eururo.2016.02.029. Epub 2016 Feb 28.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dina Gamal Abdelaziz (01147625820, dinagamal481997@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes (time frame: Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patient in period from 2010 -2024). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06730997, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2024.